企業プロフィール
Werewolf Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- HOWL
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
0.41 USD (+0.20%)
終値
最終更新: 2026年8月17日
20.9M USD
時価総額
株価変動の要因
As of Aug 17, 2026, HOWL was little changed and closed at $0.4055. No new same-company headline was identified in the current news window.
企業概要
Conditionally Activated Immunotherapy Platform
Werewolf Therapeutics is a clinical-stage biopharmaceutical company developing conditionally activated immune therapies for cancer and other immune-mediated diseases. Its technology is designed to stimulate immunity more selectively in disease tissue, with the goal of reducing the systemic toxicity that has limited conventional proinflammatory immune therapies.
PREDATOR, INDUKINE, and INDUCER Programs
The company's PREDATOR platform supports two related drug design approaches. INDUKINE molecules are engineered cytokines intended to remain inactive in peripheral tissue and activate preferentially in the tumor microenvironment. INDUCER molecules build on the same conditional activation logic but are directed toward immune stimulation against tumor-associated targets.
Clinical Cytokine Assets
Werewolf's most advanced clinical candidates are WTX-124 and WTX-330, systemically delivered and conditionally activated IL-2 and IL-12 INDUKINE molecules for solid tumors. These programs anchor the company's clinical-stage oncology profile and provide the key data readouts for validating whether conditional cytokine activation can improve therapeutic index.
Strategic Alternatives and Platform Optionality
Werewolf sold the JZP898 program to Jazz Pharmaceuticals and used the proceeds to repay its K2 HealthVentures loan. The company is now evaluating strategic alternatives with Piper Sandler while continuing to support its INDUKINE and INDUCER programs. This makes Werewolf a platform company with meaningful scientific optionality but also a near-term strategic-decision overhang.
今後のカタリスト
- Clinical data updates for WTX-124 and WTX-330 expected in the second half of 2026.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。